Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766543 | 0.87 | TSHR (0.54) | KAT6ATSHRALDH1A1HSD17B10TDP1 | |
| SCHEMBL5305260 | 0.84 | TSHR (0.56) | KAT6ATSHRALDH1A1HSD17B10TDP1 | |
| SCHEMBL28022700 | 0.83 | PTGS2 (0.51) | KAT6APTPRCPTPN1BRD4PTGS2 | |
| SCHEMBL14120596 | 0.83 | KAT6A (0.50) | KAT6APTPRCPTPN1ALDH1A1HSD17B10 | |
| SCHEMBL14161390 | 0.83 | CA1 (0.55) | KAT6APTPRCPTPN1PTGES2BRD4 | |
| SCHEMBL6846678 | 0.81 | ALDH1A1 (0.50) | TSHRALDH1A1HSD17B10TDP1SMN1; SMN2 | |
| SCHEMBL2891953 | 0.80 | TSHR (0.50) | PTPRCPTPN1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4159024 | 0.80 | BRD4 (0.55) | KAT6APTPRCPTPN1FFAR1GRIA4 | |
| SCHEMBL27787846 | 0.79 | TSHR (0.46) | KAT6ATSHRALDH1A1HSD17B10TDP1 | |
| SCHEMBL308891 | 0.79 | KAT6A (0.53) | KAT6ATSHRALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093245-B2 | Anticancer agents; potent Deoxycytidine kinase inhibitors; inhibit thymidine kinase; inhibit uridine kinase; N-[3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentyl]-3-bromo-benzenesulfonamide | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2121632-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080182847-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-07-31 | — | — | US | disclosed |
| WO-2008076778-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182847-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | TPMT, DHFR, GLS2 | KAT6A 2495/4885PTPRC 1104/4885PTPN1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.